Latest News and Press Releases

Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreementCompany in discussions with bondholders to restructure the company’s...

Ad hoc announcement pursuant to Art. 53 LR Company enters into exclusive negotiations with an undisclosed party for global rights to aprocitentanCompany to streamline the business, resulting in cost...

Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. Highlights Net...

Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of...

Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults...

Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil, Switzerland – September 5, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024. Business highlights ...

Idorsia receives approval from the European Commission (EC) for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO...